Recombinant B87 and HLJ0504 VP2 Vaccines Protect Chickens Against Infectious Bursal Disease.
- 1International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.
- 2Longhu Laboratory, Zhengzhou 450046, China.
Abstract
Infectious bursal disease virus (IBDV) causes immunosuppression and bursal damage in chickens, and safer recombinant vaccines that provide durable protection are needed. This study compared the antigenicity, immunogenicity, protective efficacy, safety and antibody persistence of unpurified VP2 preparations and purified VP2 virus-like particles (VLPs) derived from the B87 and HLJ0504 IBDV strains. Recombinant VP2 proteins were expressed in Escherichia coli, purified and characterized, formulated with oil adjuvant and evaluated in specific-pathogen-free White Leghorn chickens. Both VP2 proteins retained antigenicity and assembled into relatively uniform VLPs of approximately 25 nm. Purified VLPs induced stronger antibody responses than corresponding unpurified preparations, with 10 µg producing the highest responses. In a virus neutralization assay, HLJ0504 VP2-based preparations induced the highest neutralizing-antibody titers. Following challenge with virulent IBDV BC6/85, 10 µg of HLJ0504 VLPs and unpurified HLJ0504 VP2 at an agar-gel precipitation titer of 1:10 each protected nine of 10 chickens, similar to a commercial inactivated vaccine, and preserved bursal architecture. No systemic or injection-site adverse reactions were detected and selected recombinant vaccines maintained elevated serum-antibody levels for 20 weeks. Thus, HLJ0504 VP2-based vaccines, particularly the VLPs formulation, are promising safe and protective candidates for controlling infectious bursal disease.
Related
- Immunogenicity and Efficacy of CpG-Adjuvanted In-Ovo Recombinant HVT-LT and FPV-LT Vaccines Against Infectious Laryngotracheitis Challenge in 14-Day-Old Broiler Chickens.
- Preliminary association between infectious bronchitis virus viral load and the tracheal microbiome of broiler chickens
- Development and diagnostic validation of a recombinant Hexon L1-based indirect enzyme-linked immunosorbent assay for detecting antibodies to fowl adenovirus serotype 8b in chickens.
- Recombinant GI-19 infectious bronchitis virus induction of humoral immunosuppression with reduced HI antibody response following Newcastle disease virus vaccination and bursal cell apoptosis
- Mice immunized with N1 neuraminidase in a single cycle infectious virus or in a recombinant nanoparticle vaccine are protected against lethal challenge with highly pathogenic avian influenza H5N1 influenza
BibTeX
@article{asif2026recombinant,
title = {{Recombinant B87 and HLJ0504 VP2 Vaccines Protect Chickens Against Infectious Bursal Disease.}},
author = {Tayyab Ali Asif and Pengyu Chen and Jiahao Li and Jing Zhang and Pengchao Ji and Dawei Jiang},
journal = {Veterinary sciences},
year = {2026},
month = sep,
doi = {10.3390/vetsci13101033},
url = {https://europepmc.org/article/MED/42944129},
note = {CC BY},
}
RIS
TY - JOUR
TI - Recombinant B87 and HLJ0504 VP2 Vaccines Protect Chickens Against Infectious Bursal Disease.
AU - Tayyab Ali Asif
AU - Pengyu Chen
AU - Jiahao Li
AU - Jing Zhang
AU - Pengchao Ji
AU - Dawei Jiang
PY - 2026
DA - 2026/09/29
JO - Veterinary sciences
DO - 10.3390/vetsci13101033
UR - https://europepmc.org/article/MED/42944129
AB - Infectious bursal disease virus (IBDV) causes immunosuppression and bursal damage in chickens, and safer recombinant vaccines that provide durable protection are needed. This study compared the antigenicity, immunogenicity, protective efficacy, safety and antibody persistence of unpurified VP2 preparations and purified VP2 virus-like particles (VLPs) derived from the B87 and HLJ0504 IBDV strains. Recombinant VP2 proteins were expressed in Escherichia coli, purified and characterized, formulated with oil adjuvant and evaluated in specific-pathogen-free White Leghorn chickens. Both VP2 proteins retained antigenicity and assembled into relatively uniform VLPs of approximately 25 nm. Purified VLPs induced stronger antibody responses than corresponding unpurified preparations, with 10 µg producing the highest responses. In a virus neutralization assay, HLJ0504 VP2-based preparations induced the highest neutralizing-antibody titers. Following challenge with virulent IBDV BC6/85, 10 µg of HLJ0504 VLPs and unpurified HLJ0504 VP2 at an agar-gel precipitation titer of 1:10 each protected nine of 10 chickens, similar to a commercial inactivated vaccine, and preserved bursal architecture. No systemic or injection-site adverse reactions were detected and selected recombinant vaccines maintained elevated serum-antibody levels for 20 weeks. Thus, HLJ0504 VP2-based vaccines, particularly the VLPs formulation, are promising safe and protective candidates for controlling infectious bursal disease.
SN - 2306-7381
ER -